Table 1.

Characteristics of RCTs included in the meta-analysis

ReferenceaTrial PhaseNo. EnrolledNo. for AnalysisDuration of Follow-up (Months; Median [Range])Tumor TypeConcurrent TreatmentBevacizumab Dosage (mg/kg per wk)bCTC Version
Allegra et al.,23 200832710264722.4 (NA)CRCFluorouracil, oxaliplatin, and leucovorin2.53
Escudier et al.,11 2007364964113.3 (0.0 to 25.6)RCCInterferon alfa5.03
Giantonio et al.,18 2007382957228.0 (NA)CRCOxaliplatin, fluorouracil, and leucovorin5.02
Hurwitz et al.,17 2004381379018.0 (NA)CRCIrinotecan, bolus fluorouracil, and leucovorin2.52
Kabbinavar et al.,19 2005220920414.8 (NA)CRCBolus fluorouracil and leucovorin2.52
Karrison et al.,12 2007211510815.1 (NA)MesotheliomaCisplatin and gemcitabine5.0NA
Kindler et al.,13 2007360254011.3 (NA)Pancreatic cancerGemcitabine5.0NA
Miles et al.,14 2008373673010.2 (0.0 to 17.5)Breast cancerDocetaxel2.5 or 5.0NA
Miller et al.,21 2005346244514.8 (NA)Breast cancerCapecitabine5.02
Miller et al.,20 2007372271125.9 (NA)Breast cancerPaclitaxel5.02
Price et al.,42 20083400313NACRCCapecitabine or mitomycin2.5NA
Reck et al.,15 200931043986NANSCLCCisplatin and gemcitabine2.5 or 5.03
Rini et al.,8 20083732715NARCCInterferon alfa5.03
Saltz et al.,7 200831401136927.6 (NA)CRCOxaliplatin, fluorouracil, and leucovorin or capecitabine and oxaliplatin2.53
Sandler et al.,22 2006387886719.0 (NA)NSCLCPaclitaxel and carboplatin5.02
Van Cutsem et al.,16 200936075836.7 (NA)Pancreatic cancerGemcitabine and erlotinib2.53
  • CTC, Common Terminology Criteria; NA, not available.

  • aFunding sources: Seven trials were sponsored by Genentech,10,17,19,20,21,43,44 five trials were sponsored by Hoffman Roche,7,11,14–16 and six trials were sponsored by the National Cancer Institute and the National Institutes of Health.8,9,13,18,20,22,23 One trial was supported by the Mesothelioma Applied Research Foundation.12 One trial was supported by the Australian Gastrointestinal Trials Group.42

  • bDosage was converted from mg/kg schedule.